Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy.
Rapidly progressive disease due to acyclovir-resistant herpes simplex has not been described. We report such a case and detail successful patient management using viral sensitivities and plasma acyclovir levels to guide therapy. Response was correlated with plasma levels above those inhibiting viral growth by 50% (ID50) in vitro.
Bean
B
B
Department of Laboratory Medicine and Pathology, University of Minnesota Health Sciences Center, Minneapolis.
Fletcher
C
C
Englund
J
J
Lehrman
S N
SN
Ellis
M N
MN
D000212:Acyclovir / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D004352:Drug Resistance, Microbial; D006561:Herpes Simplex / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007635:Keratitis, Dendritic / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D010746:Phosphonoacetic Acid / Q000494:pharmacology; D018139:Simplexvirus / Q000187:drug effects*; D014740:Vidarabine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
D014740:Vidarabine; D010746:Phosphonoacetic Acid; D000212:Acyclovir